NEW YORK, Oct. 05, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Endo International plc (NASDAQ:ENDP) from November 30, 2012 through July 6, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Endo investors under the federal securities laws.
To join the Endo class action, go to http://rosenlegal.com/cases-1206.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 17, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1206.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 



